ZA200800981B - Use of SDF-1 for the treatment and/or prevention of neurological diseases - Google Patents
Use of SDF-1 for the treatment and/or prevention of neurological diseasesInfo
- Publication number
- ZA200800981B ZA200800981B ZA200800981A ZA200800981A ZA200800981B ZA 200800981 B ZA200800981 B ZA 200800981B ZA 200800981 A ZA200800981 A ZA 200800981A ZA 200800981 A ZA200800981 A ZA 200800981A ZA 200800981 B ZA200800981 B ZA 200800981B
- Authority
- ZA
- South Africa
- Prior art keywords
- sdf
- prevention
- treatment
- neurological diseases
- neurological
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 title 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110206 | 2005-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200800981B true ZA200800981B (en) | 2009-04-29 |
Family
ID=35967039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200800981A ZA200800981B (en) | 2005-10-31 | 2006-10-30 | Use of SDF-1 for the treatment and/or prevention of neurological diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080253996A1 (xx) |
| EP (1) | EP1942940A2 (xx) |
| JP (1) | JP2009513689A (xx) |
| KR (1) | KR20080060226A (xx) |
| CN (1) | CN101300031A (xx) |
| AR (1) | AR058173A1 (xx) |
| AU (1) | AU2006310577B2 (xx) |
| BR (1) | BRPI0617823A2 (xx) |
| CA (1) | CA2617598A1 (xx) |
| EA (1) | EA015716B1 (xx) |
| NZ (1) | NZ565639A (xx) |
| UA (1) | UA96926C2 (xx) |
| WO (1) | WO2007051785A2 (xx) |
| ZA (1) | ZA200800981B (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696309B2 (en) * | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| US9308277B2 (en) | 2010-02-25 | 2016-04-12 | Mesoblast International Sàrl | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| US9249204B2 (en) * | 2011-06-01 | 2016-02-02 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| WO2012170495A1 (en) * | 2011-06-07 | 2012-12-13 | Provasculon, Inc. | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 |
| US11419916B2 (en) * | 2012-09-11 | 2022-08-23 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
| US9797910B2 (en) | 2013-06-19 | 2017-10-24 | Merck Sharp & Dohme Corp. | Assay for determining endogenous levels of analyte in vivo |
| CN106796621B (zh) * | 2014-09-10 | 2021-08-24 | 皇家飞利浦有限公司 | 图像报告注释识别 |
| ITUA20161364A1 (it) | 2016-03-04 | 2017-09-04 | Antonino Cattaneo | Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche. |
| WO2018144817A1 (en) * | 2017-02-03 | 2018-08-09 | Vicapsys, Inc. | Modified cxcl12 polypeptides and uses thereof |
| CN107325187B (zh) * | 2017-07-19 | 2021-11-09 | 黄子为 | 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物 |
| US11553871B2 (en) | 2019-06-04 | 2023-01-17 | Lab NINE, Inc. | System and apparatus for non-invasive measurement of transcranial electrical signals, and method of calibrating and/or using same for various applications |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992013095A1 (en) | 1991-01-18 | 1992-08-06 | Synergen, Inc. | Methods for treating tumor necrosis factor mediated diseases |
| CA2117953C (en) * | 1993-10-14 | 2001-12-11 | Tasuku Honjo | Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| WO1999047158A2 (en) * | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| CA2245224A1 (en) * | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
| US7157418B1 (en) * | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| DE10027383A1 (de) * | 2000-06-02 | 2001-12-20 | Rhein Biotech Proz & Prod Gmbh | Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz |
| US20040037811A1 (en) * | 2002-08-22 | 2004-02-26 | The Cleveland Clinic Foundation | Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy |
| EP1493438A1 (en) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states |
| EP1685151A4 (en) * | 2003-10-31 | 2009-04-22 | Neuren Pharmaceuticals Ltd | PEPTIDES FOR THE REGENERATION OF NERVES AND METHOD FOR THEIR APPLICATION IN THE TREATMENT OF BRAIN DAMAGES |
-
2006
- 2006-10-30 WO PCT/EP2006/067949 patent/WO2007051785A2/en not_active Ceased
- 2006-10-30 CN CNA2006800404916A patent/CN101300031A/zh active Pending
- 2006-10-30 US US12/067,224 patent/US20080253996A1/en not_active Abandoned
- 2006-10-30 CA CA002617598A patent/CA2617598A1/en not_active Abandoned
- 2006-10-30 AU AU2006310577A patent/AU2006310577B2/en not_active Ceased
- 2006-10-30 UA UAA200802964A patent/UA96926C2/ru unknown
- 2006-10-30 EP EP06807673A patent/EP1942940A2/en not_active Ceased
- 2006-10-30 KR KR1020087007031A patent/KR20080060226A/ko not_active Ceased
- 2006-10-30 EA EA200801244A patent/EA015716B1/ru not_active IP Right Cessation
- 2006-10-30 ZA ZA200800981A patent/ZA200800981B/xx unknown
- 2006-10-30 JP JP2008538353A patent/JP2009513689A/ja active Pending
- 2006-10-30 BR BRPI0617823-5A patent/BRPI0617823A2/pt not_active IP Right Cessation
- 2006-10-30 NZ NZ565639A patent/NZ565639A/en not_active IP Right Cessation
- 2006-10-31 AR ARP060104776A patent/AR058173A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1942940A2 (en) | 2008-07-16 |
| BRPI0617823A2 (pt) | 2011-08-09 |
| AR058173A1 (es) | 2008-01-23 |
| AU2006310577A1 (en) | 2007-05-10 |
| US20080253996A1 (en) | 2008-10-16 |
| UA96926C2 (ru) | 2011-12-26 |
| JP2009513689A (ja) | 2009-04-02 |
| EA015716B1 (ru) | 2011-10-31 |
| CN101300031A (zh) | 2008-11-05 |
| AU2006310577B2 (en) | 2012-04-19 |
| CA2617598A1 (en) | 2007-05-10 |
| KR20080060226A (ko) | 2008-07-01 |
| NZ565639A (en) | 2012-03-30 |
| EA200801244A1 (ru) | 2009-02-27 |
| WO2007051785A3 (en) | 2007-09-07 |
| WO2007051785A2 (en) | 2007-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
| ZA200804646B (en) | The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases | |
| EP1968607A4 (en) | TREATMENT OF CANCER AND OTHER DISEASES | |
| ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
| ZA200801706B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
| AP2007004245A0 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| ZA200800452B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
| IL184124A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| ZA200800448B (en) | Methods and compositions for the prevention and treatment of inflammatory disease | |
| ZA200708819B (en) | Methods and compositions for the prevention and treatment of kidney disease | |
| EP1680145A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
| IL187405A0 (en) | Methods and compositions for the treatment of pain | |
| ZA200800981B (en) | Use of SDF-1 for the treatment and/or prevention of neurological diseases | |
| ZA200707955B (en) | Methods and pharmaceutical compositions for the treatment of neurological damage | |
| GB0523961D0 (en) | The treatment of ophthalmic diseases | |
| EP1740221A4 (en) | METHOD AND COMPOSITIONS FOR TREATING POLYCYSTIC DISEASES | |
| EP1812797A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERPROLIFERATIVE DISEASES | |
| EP1781318A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES | |
| IL190842A0 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
| GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
| IL180526A0 (en) | Composition for the prevention and treatment of allergic inflammatory disease | |
| GB0523964D0 (en) | The treatment of ophthalmic diseases | |
| ZA200710476B (en) | Methods and compositions for the treatment of pain | |
| GB0513413D0 (en) | The treatment of inflammatory disorders and pain |